Loading
TT
Trevi Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Apr 2022.
Trevi Therapeutics, Inc.: what insiders have been doing
Trevi Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 7 filings signed by 3 insiders.
No insider bought on the market over the period, while 1 insider filed 3 sales totalling €515k. Biggest ticket of the year: €274k, sold by Heffernan Michael Thomas and made public on 17 September 2026 (0.015% of market cap).
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 7 filings, this issuer sits below that mark. Our records for Trevi Therapeutics, Inc. go back to 2021, with 10 purchases and 7 sales on the open market in total.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
55
Thresholds
n/a
Buy Volume
€5M
10 ops. · all time
Sell Volume
€2M
7 ops. · all time
Who traded when
BuySaleMichael Thomas Heffernan3 sales
Since the insiders bought
- -42.4%Entry US$3.28 · Close at T+365 US$1.89
- +53.5%Entry US$1.27 · Close at T+365 US$1.95
- +53.5%Entry US$1.27 · Close at T+365 US$1.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Trevi Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$28.18.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.88
Analyst consensus
11 analystsStrong buy
US$23.00Target US$28.18(+137%)US$40.00
Income statement
EBITDA-US$42.7M
Net income-US$42.8M0.0% margin
Valuation
PER (forward)-20.6x
P/Book5.3x
Beta0.98
Balance sheet & cash
Market capUS$1.7B
Total debtUS$753k
Free Cash Flow-US$42.1M
Debt / Equity0%
Profitability & ownership
ROE-19.7%
ROA-13.8%
% insiders0.6%
% institutions109.1%
Last declaration on 17 September 2026
Declarations55 total
18,321 shares@ US$15.090.013% mcap38.4% of flowCommon StockSEC:0001193125-26-394456:1
18,421 shares@ US$3.040.0027% mcap7.8% of flowCommon StockSEC:0001193125-26-394456:0
100 shares@ US$15.880.0001% mcap0.2% of flowCommon StockSEC:0001193125-26-394456:2
21,052 shares@ US$3.330.0034% mcap9.7% of flowCommon StockSEC:0001193125-26-394456:3
20,952 shares@ US$15.090.015% mcap43.9% of flowCommon StockSEC:0001193125-26-394456:4
39,473 shares@ US$15.89100.0% of flowCommonSEC144:0001950047-26-009512
4,225 shares@ US$0.51120.3% of flowCommon StockSEC:0001193125-25-306729:0
2,631 shares@ US$1.432.4% of flowCommon StockSEC:0000950170-25-045295:0
5,263 shares@ US$1.439.0% of flowCommon StockSEC:0000950170-25-044436:0
17,500 shares@ US$3.2181.3% of flowCommon StockSEC:0000950170-25-037880:0
1,000 shares@ US$0.5111.6% of flowCommon StockSEC:0000950170-25-004164:0
15,000 shares@ US$0.51179.7% of flowCommon StockSEC:0000950170-24-137255:0
4,219 shares@ US$1.437.0% of flowCommon StockSEC:0000950170-24-104804:0
3,863 shares@ US$1.436.5% of flowCommon StockSEC:0000950170-24-104061:0
4,555 shares@ US$1.43100.0% of flowCommon StockSEC:0000950170-24-101926:0
16,496 shares@ US$1.4314.7% of flowCommon StockSEC:0000950170-24-099481:0
100 shares@ US$1.430.1% of flowCommon StockSEC:0000950170-24-098117:0
59,354 shares@ US$2.1982.9% of flowCommon StockSEC:0000950170-24-067305:0
16,043 shares@ US$0.51125.3% of flowCommon StockSEC:0000950170-24-064598:0
25,037 shares@ US$2.1965.4% of flowCommon StockSEC:0000950170-24-063531:0
4,578 shares@ US$2.1912.1% of flowCommon StockSEC:0000950170-24-059722:0
2,292 shares@ US$0.5113.7% of flowCommon StockSEC:0001209191-23-052687:0
2,291 shares@ US$0.5113.6% of flowCommon StockSEC:0001209191-23-049252:0
2,292 shares@ US$0.5113.6% of flowCommon StockSEC:0001209191-23-045595:0
2,292 shares@ US$0.5113.6% of flowCommon StockSEC:0001209191-23-042078:0
25 of 55 declarations
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (NASDAQ, United States) is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine extended-release) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The company was founded in 2011 and is headquartered in New Haven, Connecticut, placing it within a mature U.S. life-sciences cluster with access to specialized clinical, regulatory, and financing ecosystems. ([trevitherapeutics.com](https://www.trevitherapeutics.com/about-2/))
From an industry perspective, Trevi is best viewed as a development-stage biotech with a highly concentrated pipeline. Its near-term equity story is overwhelmingly driven by Haduvio, which Trevi describes as an investigational therapy acting on the cough reflex arc both centrally and peripherally through a kappa agonist / mu antagonist mechanism. The company has reported positive Phase 2b CORAL data in IPF-related chronic cough and positive Phase 2a RIVER data in RCC, which provides clinical validation, but Haduvio remains unapproved and its safety and efficacy have not been evaluated by any regulatory authority. ([trevitherapeutics.com](https://www.trevitherapeutics.com/about-2/))
Read moreShow less
Trevi’s competitive position is tied to an important unmet medical need. Chronic cough associated with pulmonary disease, and RCC more broadly, have limited targeted treatment options, so a therapy that can demonstrate meaningful reductions in cough frequency could be commercially attractive. Trevi states that Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency across both IPF chronic cough and RCC clinical trials. That claim supports a potentially differentiated profile, although investors should remember that the company is still in a high-risk development phase and success will depend on further trial execution, regulatory outcomes, and eventual commercialization readiness. ([ir.trevitherapeutics.com](https://ir.trevitherapeutics.com/news-releases/news-release-details/trevi-therapeutics-announces-pricing-150-million-underwritten))
Geographically, the business is primarily U.S.-based today, with headquarters in New Haven and capital-market access through the NASDAQ in the United States. For international investors, that means the stock should be assessed as a U.S. biotech: binary-ish clinical catalysts, dilution risk, and a funding profile that matters as much as the science. In March and April 2026, Trevi highlighted its year-end 2025 results and then announced a $150 million underwritten equity offering, underscoring the capital intensity of advancing the program. The company had previously ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, and later reported year-end 2025 cash, marketable securities, and a continuing net loss typical of a company still investing heavily in R&D. ([ir.trevitherapeutics.com](https://ir.trevitherapeutics.com/2025-03-18-Trevi-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Business-Updates?asPDF=1&utm_source=openai))
Recent news flow has therefore centered on financing, scientific presentations, and investor communication, including the company’s 2026 earnings updates, ATS conference presentations, and investor/analyst day messaging. In practical terms, Trevi is a specialized U.S. NASDAQ-listed biotech where the investment thesis hinges on Haduvio’s clinical differentiation and eventual regulatory path rather than diversified operations or near-term product revenue. ([ir.trevitherapeutics.com](https://ir.trevitherapeutics.com/))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
